Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights several risks, including regulatory delays, financial stability concerns, and competitive pressures. The Q&A section reveals management's vague responses and lack of clarity, further undermining confidence. Despite some positive aspects like reduced operating expenses and meeting certain efficacy requirements, the overall sentiment leans negative due to these uncertainties and risks.
Key Financial Performance
Cash on Hand Approximately $13 million, which includes roughly $9 million raised in February 2025, taking the company into the third quarter of 2025.
Operating Expenses Reduced by about $3 million in 2024 compared to 2023.
Market Capitalization Current market cap is $16.2 million, up from year-end due to the issuance of equity in February 2025.
Shares Outstanding 14 million shares outstanding.
Trading Volume Trailing one-year trading volume is 1.4 million shares per day.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Annamycin: Moleculin is focused on the launch of the MIRACLE Phase 3 pivotal trial for Annamycin, designed for the second line treatment of relapsed and refractory AML patients.
Market Cap: Current market cap is $16.2 million, up from year-end due to equity issuance in February 2025.
Cash Balance: Combined cash balance of approximately $13 million, taking the company into the third quarter of 2025.
Operating Expenses: Reduced operating expenses in 2024 by about $3 million compared to 2023.
MIRACLE Trial: The MIRACLE trial will have multiple unblindings of data, allowing stakeholders to track progress, with the first unblinding expected after 45 subjects are treated.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The US is expected to be one of the last countries to begin enrolling in the MIRACLE trial due to longer approval processes involving institutional review boards, ethics committees, and hospital contract negotiations.
Clinical Trial Risks: The Phase 3 MIRACLE trial's success hinges on achieving a statistically significant complete remission rate greater than 17.5% compared to the control arm, which poses a risk if the drug does not perform as expected.
Funding and Financial Stability: The company has a cash balance of approximately $13 million, which is projected to last until the third quarter of 2025, indicating potential financial risks if additional funding is not secured.
Market Competition: Moleculin faces competitive pressures from existing therapies in the AML market, which may impact the adoption of Annamycin if it does not demonstrate superior efficacy.
Data Reliability: The company relies on third-party sources for some data, which may not be independently verified, posing a risk to the credibility of the information presented.
Patient Enrollment: The timeline for patient enrollment may be affected by the regulatory and approval processes in various countries, potentially delaying the trial's progress.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
MIRACLE Phase 3 Trial Launch: Moleculin is focused on launching the MIRACLE Phase 3 pivotal trial for Annamycin in combination with Cytarabine for relapsed and refractory AML patients, with 25 sites selected globally.
Patient Screening and Enrollment: Patient screening has begun, with expectations to treat the first patient in Q1 2025, although US enrollment may be delayed.
Data Unblinding: The trial will have multiple unblindings of data, with the first at 45 subjects expected by the end of 2025 and a second at 75-90 subjects in the first half of 2026.
Financial Management: Moleculin has reduced operating expenses by $3 million in 2024 and raised approximately $9 million in February 2025, providing a cash balance of $13 million to fund operations into Q3 2025.
Revenue Expectations: Moleculin anticipates significant milestones in 2025, including data readouts and potential early approval for Annamycin.
Market Capitalization: Current market cap is $16.2 million with 14 million shares outstanding.
Operational Milestones: Expectations for 2025 include updates on trial site approvals, data readouts, and the initiation of a pivotal investigator-initiated trial in Europe.
Future Projections: Moleculin aims to leverage Annamycin's unique properties to address unmet needs in AML and other cancers, with a focus on operational execution and meeting milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Market Cap: $16.2 million
Shares Outstanding: 14 million shares
Cash Balance: $13 million (including $9 million raised in February 2025)
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What efficacy is required to pick one Annamycin dose at 45 patients rather than waiting until 90 if it doesn’t happen at 45?
A:Management indicated that it is a multivariable equation and speculated that if Annamycin performs as well as in the Phase 2 trial and HiDAC performs as expected, they could achieve the statistical significance needed to shorten the trial. However, they also noted that HiDAC might underperform due to limitations in the trial.
Q:What was the thinking that went into cutting off about 10% of patients from Part D?
A:Management stated that the decision was influenced by the FDA's recommendations for a different biostatistical scheme, which allowed for a reduction in the number of patients.
Q:What is the STS lung met efficacy bogey you need to hit to proceed to an investigator-sponsored pivotal trial?
A:Management claimed they have already met the efficacy requirements, noting that the patients treated were more challenged than expected, and they are seeing strong overall survival numbers that have garnered interest from sarcoma experts.
Q:What are the overall costs of the trial?
A:Management estimated the cost of a Phase 3 trial to be upwards of $60 million to $70 million, with a cash burn of $5 million per quarter for the rest of 2025, increasing to $7-8 million in 2026.
Q:What are your thoughts on moving to frontline therapy in AML development?
A:Management agreed that first-line therapy is the ultimate objective and that they will pursue it after demonstrating approval for second-line therapy.
Q:What is the rationale for choosing the 190 dose discussions at the FDA?
A:Management explained that the 190 dose was chosen based on FDA's Project Optimus and previous efficacy seen in studies, but they could not predict which dose would ultimately be used.
Q:Will you preserve the 190 dose should any safety signals appear?
A:Management acknowledged the possibility of reverting to the 190 dose if safety issues arise with the 230 dose, but expressed confidence in the safety profile of the drug.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific efficacy required to pick one Annamycin dose at 45 patients, using vague language about multivariable equations and probabilities. Additionally, their response about the rationale for choosing the 190 dose lacked clarity, as they could not definitively predict which dose would be used.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AML patient
Annamycin dose
Annamycin regimen
Europe
MB study
MB trial
MIRACLE trial
Phase study
WP
analysis Annamycin
approval country
arm milligram
completion
control arm
dose Annamycin
durability
efficacy analysis
endpoint
ethic
hospital
line therapy
meter treatment
month
patient efficacy
patient study
placebo
process
refractory AML
selection
site country
study Annamycin
study approval
subject
survival
term
treatment arm
trial Annamycin
trial milestone
trial readout
unblinding
MBRX Transcript
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates
Unknown5-14
The earnings call presents several risks and uncertainties: regulatory delays in the EU, a significant funding need of $15 million, and potential trial complications. Despite strong Annamycin performance and optimistic guidance, these risks overshadow positives. Additionally, the lack of new partnerships or shareholder return plans dampens sentiment. Given the small market cap, the stock may react strongly to these uncertainties, likely resulting in a negative movement of -2% to -8%.
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Positive factors include the EMA approval, new drug name recognition, and patent protection for Annamycin. However, the need for $15 million in funding and regulatory risks pose significant challenges. The Q&A section reveals uncertainties, particularly concerning EU approval timelines and R&D expenses. The small market cap suggests potential volatility, but the lack of clear positive catalysts and financial uncertainties balance the sentiment, leading to a neutral prediction.
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript
Unknown3-25
The earnings call summary highlights several risks, including regulatory delays, financial stability concerns, and competitive pressures. The Q&A section reveals management's vague responses and lack of clarity, further undermining confidence. Despite some positive aspects like reduced operating expenses and meeting certain efficacy requirements, the overall sentiment leans negative due to these uncertainties and risks.
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials
Unknown3-24
The earnings call highlights both positive and negative elements. Financial performance shows improved cost management and a solid cash position, but the increasing cash burn rate and high trial costs are concerning. Product development is promising with potential accelerated approval, but uncertainties in efficacy and patient recruitment pose risks. Market strategy is unclear with management avoiding direct responses. Shareholder returns are not mentioned. Overall, these mixed signals suggest a neutral stock price movement.
MBRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
